Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clinical study for pyrrotinib combined with or without trastuzumab in the treatment of advanced her2-positive colorectal cancer

ABSTRACT: Interventions: Pyrrotinib combined with trastuzumab:oral Pyrrotib maleate tablets, initial dose 400 mg/day, taken within 30 min after breakfast, once a day, continuous administration, 21 days per cycle. Trastuzumab for injection: intravenous infusion with an initial loading dose of 8mg/kg followed by 6mg/kg. The first infusion takes approximately 90 minutes.;Pyrrotinib alone:Oral Pyrrotib maleate tablets by initial dose of 400 mg/day, taken within 30 min after breakfast, once a day, continuous administration, 21 days per treatment cycle. Primary outcome(s): objective response rate Study Design: Non randomized control

DISEASE(S): Her2-positive Advanced Colorectal Cancer

PROVIDER: 2689432 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Single center, single arm, prospective and open clinical study of pyrroltinib maleate tablets and trastuzumab combined with FOLFOX6 regimen in the preoperative treatment of HER-2 positive colorectal cancer

Project description:Interventions: HER-2 positive colorectal cancer:pyrroltinib maleate tablets and trastuzumab combined with FOLFOX6 regimen Primary outcome(s): pCR Study Design: Single arm

| 2698207 | ecrin-mdr-crc

Phase 2/3 study of fluoropyrimidine and irinotecan plus bevacizumab versus trifluridine/tipiracil plus bevacizumab as second-line for metastatic colorectal cancer (TRUSTY)

Project description:Intervention name : trifluridine/tipiracil INN of the intervention : trifluridine/tipiracil Dosage And administration of the intervention : Trifluridine/tipiracil was given in a dose of 35-75 mg twice daily (after breakfast and dinner) (70-150 mg/day) from after dinner on Day 1 to after breakfast on Day 6 and from after dinner on Day 8 to after breakfast on Day 13. Treatment was given orally for 5 consecutive days followed by a 2-day rest. This treatment was repeated twice, followed by a 14-day rest. This 28-day cycle was repeated until the criteria for withdrawal of the study treatment were met. Intervention name : bevacizumab INN of the intervention : bevacizumab Dosage And administration of the intervention : Bevacizumab 5 mg/kg was given as a 30-min continuous intravenous infusion on Day 1 and Day 15. Control intervention name : fluorouracil INN of the control intervention : fluorouracil Dosage And administration of the control intervention : [Treatment with FOLFIRI + bevacizumab] Fluorouracil 400 mg/m2 was given by rapid intravenous injection on Day 1, followed by a 46-h continuous intravenous infusion of 2400 mg/m2. Each cycle was 14 days, and treatment was repeated until the criteria for withdrawal of the study treatment were met. Control intervention name : TS-1(tegafur + gimeracil + oteracil potassium) INN of the control intervention : TS-1(tegafur + gimeracil + oteracil potassium) Dosage And administration of the control intervention : [Treatment with TS-1+ irinotecan +bevacizumab (3-week cycles) ] TS-1 is given orally in a dose of 40-60 mg twice daily (after breakfast and dinner) in accordance with body-surface area (80-120 mg/day), starting from after dinner on Day 1 to after breakfast on Day 15, followed by a 7-day rest. Each cycle was 21 days, and treatmen Primary outcome(s): efficacy Overall survival Study Design: Randomized, open-label, comparative study

| 2611617 | ecrin-mdr-crc

TRUSTY

Project description:Interventions: <Fluoropyrimidine+irinotecan+bevacizumab treatment arm> Prior to enrollment, investigator or subinvestigator select one of the following scheduled regimens for each patient. 1.FOLFIRI+bevacizumab therapy Bevacizumab 5 mg/kg is given as an intravenous infusion over the course of 30 min on Day 1. After that, irinotecan 150mg/m^2 is given as an intravenous infusion over the course of at least 90 min on Day 1. At the same time, levofolinate 200mg/ m^2 is given as an infusion of the course of 2 hours on Day1. After that, fluorouracil 400 mg/ m^2 was given by rapid intravenous injection on Day 1, followed by a 46-h continuous intravenous infusion of 2400 mg/ m^2. Each cycle was 14 days, and treatment was repeated until the criteria for withdrawal of the study treatment were met. 2. S-1+irinotecan+bevacizumab therapy with a 3-week cycle Bevacizumab 7.5 mg/kg is given as an intravenous infusion over the course of 30 min on Day 1. After that, irinotecan 150 mg/m^2 is given as an intravenous infusion over the course of at least 90 min on Day 1. S-1 is given orally in a dose of 40-60 mg twice daily (after breakfast and dinner) in accordance with body-surface area (80-120 mg/day), starting from after dinner on Day 1 to after breakfast on Day 15, followed by a 7-day rest. Each cycle was 21 days, and treatment was repeated until the criteria for withdrawal of the study treatment were met. 3. S-1+irinotecan+bevacizumab therapy with a 4-week cycle Bevacizumab 5 mg/kg is given as an intravenous infusion over the course of 30 min on Day 1 and Day 15. After that, irinotecan 100 mg/m^2 is given as an intravenous infusion over the course of at least 90 min on Day 1 and Day 15. S-1 is given orally in a dose of 40-60 mg twice daily (after breakfast and dinner) in accordance with body-sur Primary outcome(s): Overall survival Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose

| 2613990 | ecrin-mdr-crc

Modulation of the FOLFIRI-based standard 1st-line therapy with cetuximab, controlled by monitoring the RAS mutation load by liquid biopsy in RAS-mutated mCRC patients

Project description:Interventions: Group 1: FOLFIRI or mFOLFIRI (q14d) + cetuximab (q7d): o Irinotecan 180 mg/m² iv, 30 - 90 min, day 1 o Folinic acid (racemic) 400 mg/m² iv, 120 min, day 1 o [5-FU 400 mg/m² bolus, day 1] o 5-FU 2400 mg/m² iv over 46 h, day 1-2 o Cetuximab initially 400 mg/m² as a 120 min infusion (= 5 mg/min); subsequently 250 mg/m² iv as a 60 min infusion (= 10 mg/min), day 1 + 8 One cycle consists of 14 days Group 2: FOLFIRI (q14d): o Irinotecan 180 mg/m² iv, 30 - 90 min, day 1 o Folinic acid (racemic) 400 mg/m² iv, 120 min, day 1 o Fluorouracil (5-FU) 400 mg/m² bolus, day 1 o 5-FU 2400 mg/m² iv over 46 h, day 1-2 OR modified FOLFIRI (mFOLFIRI) (q14d): o Irinotecan 180 mg/m² iv, 30 - 90 min, day 1 o Folinic acid (racemic) 400 mg/m² iv, 120 min, day 1 o 5-FU 2400 mg/m² iv over 46 h, day 1-2 Primary outcome(s): The primary objective is to evaluate efficacy in terms of progression free survival (PFS) from the date of randomization in the study according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria in experimental and control arms. Study Design: Allocation: Randomized controlled study; Masking: Open (masking not used); Control: active; Assignment: parallel; Study design purpose: treatment

| 2437805 | ecrin-mdr-crc

Phase 2/3 study of fluoropyrimidine and irinotecan plus bevacizumab versus trifluridine/tipiracil plus bevacizumab as second-line for metastatic colorectal cancer (TRUSTY)

Project description:Interventions: investigational material(s) Generic name etc : trifluridine/tipiracil INN of investigational material : trifluridine/tipiracil Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Trifluridine/tipiracil was given in a dose of 35-75 mg twice daily (after breakfast and dinner) (70-150 mg/day) from after dinner on Day 1 to after breakfast on Day 6 and from after dinner on Day 8 to after breakfast on Day 13. Treatment was given orally for 5 consecutive days followed by a 2-day rest. This treatment was repeated twice, followed by a 14-day rest. This 28-day cycle was repeated until the criteria for withdrawal of the study treatment were met. Generic name etc : bevacizumab INN of investigational material : bevacizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Bevacizumab 5 mg/kg was given as a 30-min continuous intravenous infusion on Day 1 and Day 15. control material(s) Generic name etc : fluorouracil INN of investigational material : fluorouracil Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material : [Treatment with FOLFIRI + bevacizumab] Fluorouracil 400 mg/m2 was given by rapid intravenous injection on Day 1, followed by a 46-h continuous intravenous infusion of 2400 mg/m2. Each cycle was 14 days, and treatment was repeated until the criteria for withdrawal of the study treatment were met. Generic name etc : TS-1(tegafur + gimeracil + oteracil potassium) INN of investigational material : TS-1(tegafur + gimeracil + oteracil potassium) Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material : [Treatment with TS-1+ irinotecan +bevacizumab (3- Primary outcome(s): efficacy Overall survival Study Design: Randomized, open-label, comparative study

| 98099 | ecrin-mdr-crc

Phase 2 trial of FOLFIRI plus ziv-aflibercept in patients with colorectal cancer previously treated with oxaliplatin, fluoropyrimidins, bevacizumab, and trifluridine/tipiracil

Project description:Interventions: FOLFIRI plus ziv-aflibercept (Day 1) Ziv-aflibercept, 4 mg/kg, intravenously (IV) over 60 min (Day 1) Irinotecan, 150 mg/m2, IV over 90 min (Day 1) Leucovorin (l-LV), 200 mg/m2, IV over 120 min (Day 1) 5-FU, 400 mg/m2, bolus (Day 1-3) 5-FU, 2400 mg/m2, continuous infusion over 46 h Repeat the above every two weeks The dose of irinotecan can be reduced to 120 mg/m2 if patients are homozygous for UGT1A1*28 or UGT1A1*6, or heterozygous for both UGT1A1*28 and UGT1A1*6.;C480833,C533178;FOLFIRI, ziv-aflibercept Primary outcome(s): progression free survival Study Design: single arm study, open(masking not used), historical control, single assignment, treatment purpose

| 2614963 | ecrin-mdr-crc

Healthy adults' blood gene expression who ingested Salacia reticulata plant extract

Project description:In human volunteers, we evaluated changes in gene expression profiles, immunological indices, and intestinal microbiota of blood cells in subjects consuming a S.reticulata extract. Thirty healthy Japanese males were split randomly into a group ingesting 240 mg/day of S.reticulata extract -containing tablets for 4 weeks and a control group ingesting placebo tablets. Ingestion of the S.reticulata extract improved T cell proliferation and other immunological indices, and changed intestinal microbiota, increasing Bifidobacterium and Lactobacillales and decreasing Clostridium bacteria. Expression levels of many immuno-relevant genes were altered. We have shown the S.reticulata extract to enhance human immune functions.

2017-02-11 | GSE66449 | GEO

Bioequivalence study of Capecitabine 500 mg with XelodaÂ(capecitabine) tablets 500 mg in Locally Advanced Breast Cancer or Metastatic Breast Cancer or Colorectal Cancer patients under fed condition

Project description:Intervention1: Capecitabine Tablets 500mg: Capecitabine Tablets 500 mg will be administered as a single oral dose as multiples of 500mg on Day 1 and Day 2 morning dose as per randomization schedule. Control Intervention1: Xeloda tablet 500mg: Capecitabine Tablets 500 mg will be administered as a single oral dose as multiples of 500mg on Day 1 and Day 2 morning dose as per randomization schedule. Primary outcome(s): To characterise the pharmacokinetic profile of the sponsors test formulation [Capecitabine Tablets 500 mg] relative to that of reference formulation [XelodaÂ Tablets 500 mg] in patients with Metastatic Breast Cancer or Colorectal Cancer under fed condition and to assess the bioequivalence.Timepoint: The venous blood samples will be withdrawn Pre-dose and 0.25(15 min), 0.5(30 min), 1, 1.333, 1.667, 2, 2.333, 2.667, 3, 3.5, 4, 5, 6, 8, 10 hr post-dose in each period administration

| 2573902 | ecrin-mdr-crc

Glucose-dependent insulinotropic polypeptide effects in type 1 diabetes

Project description:Glucose-dependent insulinotropic polypeptide (GIP) has been proposed to exert insulin-independent effects on lipid and bone metabolism. We investigated the effect of a 6-day s.c. GIP infusion on circulating lipids, white adipose tissue (WAT), brown adipose tissue (BAT), hepatic fat content, and inflammatory markers in patients with type 1 diabetes. In a randomized, placebo-controlled, double-blind, crossover study, 20 men with type 1 diabetes underwent a 6-day continuous s.c. infusion with GIP (6 pmol/kg/min) and placebo (saline), with an interposed seven-day washout period. Each intervention period involved three study days: Day 0 (baseline measurements, a baseline abdominal adipose tissue biopsy and blood sampling), Day 1 (fasting blood sample after 24 hours infusion), and Day 6 (fasting blood sample, an abdominal adipose tissue biopsy).

2022-11-08 | PXD034803 | Pride

Analysis of transgenerational effects on DNA copy number aberrations in male mice exposed to continuous 1mGy/day gamma-rays for 400 days (Primary screening for 1mGyG familly).

Project description:Transgenerational effects of continuous low dose-rate (LDR) gamma-ray irradiation have not been well studied. Recent advances in DNA technology enabled us to examine a whole genome at molecular level. Here we adopted one of these techniques called oligo-microarray comparative genome hybridization (CGH) and studied trans-generational effects on DNA copy number aberrations (CNAs). C57BL/6J male mice were exposed to LDR gamma-rays (1 mGy/day) for 400 days (total dose: 400 mGy) from 8 weeks of age. Progeny from 1 mGy/day irradiated mice had significantly lower frequencies of genomic aberrations than the progeny of non-irradiated mice.This study investigated the De novo mutation by comparing the parents and children using 15 LDR gamma-rays (1 mGy/day) irradiated male family and 25 non irradiated male family. This is a primary screening. This study was performed under contract with the Aomori Prefectural Government, Japan.

2022-08-20 | GSE211288 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data